June 16, 2020
Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday.
The news comes months after word that the company had furloughed much of its staff, reassessed its high-profile partnership with Otsuka Pharmaceutical and shifted away from its primary focus area of mental disorder treatment.
The "smart pill" maker...
December 9, 2019
Gainesville, Florida-based etectRx has received FDA 510(k) clearance for its ID-Cap System, a prescription ingestible system that sends adherence event logs to an external medical device.
Similar to the system pioneered by etectRx’s high-profile competitor, Proteus Digital Health, the ID-Cap’s core is a standard capsule containing a sensor that transmits a message once it comes into contact with...
October 10, 2018
Children’s Health, a Texas-based pediatric health system, is teaming up with Proteus to pilot a new program aimed at tackling adherence issues in pediatric heart transplant patients by inserting ingestible sensors into prescribed pills, which can track when the medication was taken.
The system is made up of a wearable patch worn by the patient and the sensor-infused pill. When the pill is broken...
January 10, 2018
A group of researchers at RMIT University in Melbourne, Australia have developed a new ingestible sensor for a novel purpose: investigating the microbiome and gasses in the gut. In a new study published in Nature Electronics, researchers display not only the potential of the new ingestible sensor, but new learnings that suggest, among other things, a previously undiscovered defense system in the...
November 14, 2017
The first drug in the US with a digital ingestion tracking system has been approved by the FDA.
The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults.
An ingestible sensor embedded in the pill is able to record that the medication was taken – sending...
October 10, 2017
Researchers at MIT and Brigham and Women's Hospital have developed a proof-of-concept flexible sensor that can be ingested, attaches to the inside of the stomach lining, and collects and transmits data on stomach movement and meal ingestion. The device is piezoelectric, which means it can be powered by the mechanical energy generated by the stomach, allowing it to last for at least two days...
January 11, 2016
Redwood City, California-based Proteus Digital Health announced its first US healthcare provider customer, Barton Health, which will prescribe the company's Proteus Discover to patients. The company says this is the first time its technology has been implemented outside of a clinical trial setting in the US.
Barton Health, a health system in Lake Tahoe, California, will use the medication...
September 10, 2015
After years of using its digital health feedback system in clinical trials and studies, Proteus Digital Health, and partner Otsuka Pharmaceuticals, are poised to launch the first mass market drug to incorporate Proteus's ingestible sensor. The companies have submitted a sensor-embedded version of the antidepressant Abilify for FDA approval.
“Today, patients suffering from severe mental illnesses...
August 5, 2014
Proteus Digital Health
Proteus Digital Health published a paper on its ingestible sensor that explains the design of the sensor, the safety tests Proteus completed, and the clinical trials Proteus conducted with 412 patients who used the system over 5,656 days.
The Proteus digital medicine platform is a medication management and adherence system that includes unique measurement tools, like...
July 31, 2013
Proteus Digital Health, the ingestible sensor company that raised $45 million in May -- the largest funding raise in digital health this year so far -- has published the results of a small clinical trial in a peer-reviewed journal. The study of 27 adults with bipolar disorder or schizophrenia found that the addition of an ingestible sensor to their regiment led to 67 percent of patients taking...